Background

Pulmonary mycosis is a fungal infection caused by pathogenic fungi. The infection is caused by inhaling fungal spores, which attack the bronchial and lung tissues, leading to pulmonary fungal infection [9]. Pulmonary fungal infection is common among patients with a suppressed immune system due to the interruption in the fungal microflora [13]. An estimated 13 million cases of fungal infection and 1.5 million deaths have been reported across the globe, of which 60% were associated with pulmonary mycoses [3]. Conversely, pulmonary tuberculosis is a bacterial infection caused by Mycobacterium tuberculosis. The bacteria attack the lungs and destroy other organs in the body. In 2020, there will be an estimated 10 million new cases worldwide. 5.6 million men, 3.3 million women, 1.1 million children, and 1.5–2 million deaths worldwide in 2022 [8]. The mortality rate in pulmonary tuberculosis can be as high as 7% in patients with a weakened immune system [5, 10]. Similarly, pulmonary tuberculosis and mycosis are transmitted via airborne inhalation of bacterial droplets and fungal spores from infected individuals and overgrown fungal cultures in the environment. Intriguingly, pulmonary mycoses have similar manifestations, imaging features, signs, and symptoms to pulmonary tuberculosis [10, 20]. This contributed to the difficulty in diagnosing and treating pulmonary mycoses. The difficulty in treatment and diagnosis remains a significant public health threat in areas with high cases of pulmonary tuberculosis [8, 9].

The burden of pulmonary fungal infection is difficult to ascertain due to limited data in most developing countries. Despite this, opportunistic fungi, including Aspergillus species, Cryptococcus species, Pneumocystis species, and Histoplasma species, are the primary sources of fungal infections in the lungs of humans. Other endemic fungi, including Aspergillus fumigatus, Candida albicans, and Trichophyton rubrum, were associated with systemic fungal infections [2, 20]. In Nigeria, the prevalence of pathogenic fungal diseases was estimated at around 11.8%, whereas the incidence remains unclear because no central units are coordinating the surveillance of pathogenic fungal infections at the national level [9, 18]. Previous studies on treating pulmonary tuberculosis instead of mycoses were reported to affect the patient’s immunity. Thus, this exposed the susceptible patient to a pulmonary fungal infection [3, 4, 10]. Misdiagnosed and untreated acute pulmonary mycosis has an 80% chance of spreading and disseminating into chronic pulmonary mycoses with fatal consequences [9, 18, 20].

Despite advances in the diagnosis, treatment, and control of pulmonary tuberculosis and mycosis, there is a continuous increase in the number of pulmonary mycoses among patients with pulmonary tuberculosis [5, 7, 8, 18]. This study examined the level of pulmonary mycoses in patients with confirmed pulmonary tuberculosis in Kebbi State, Nigeria.

Methods

Study area

Kebbi State is located in Northern Nigeria. The state’s climate is tropical continental, influenced by tropical maritime and continental air masses. Dominant seasons are the wet and dry seasons. The temperature is generally high, with a mean annual temperature of about 26ºC in all locations. Except during the wet season, when relative humidity reaches an average of 8%, night temperatures are generally lower.

Study design

This is a hospital-based cross-sectional study conducted in the microbiology departments of five general hospitals using a gene Xpert machine to diagnose M. tuberculosis. The hospitals involved in this study are General Hospital Argungu, General Hospital Kamba, General Hospital Zuru, General Hospital Yauri, and Federal Medical Center Birnin-kebbi. Samples were collected from male and female patients positive for M. tuberculosis on the GeneXpert machine until the desired sample size was obtained. The study was carried out from July 2020 to March 2021.

Study subjects

Three hundred patients with confirmed M. tuberculosis were recruited for the study. They include (1) pulmonary tuberculosis patients with either rifampicin resistance or rifampicin-sensitive tuberculosis. (2) Patients with pulmonary tuberculosis who are not infected with pulmonary mycoses. (3) Patients with suspected cases of pulmonary mycoses infection and not on antifungal treatments. Patients with suspected pulmonary tuberculosis who did not provide sputum samples were excluded from this study. Approval to carry out this research was obtained from the Research Committee of the Kebbi State Ministry of Health. The adult participant signed informed consent, while written informed assent for minors was obtained from the guardian before sputum sample collection.

Specimen collection and processing

Sputum samples were collected in a sterile container. The samples were diagnosed using GeneXpert and fungus cultures and assays. The samples were processed in the pathology laboratory of the Federal Medical Center, Birnin Kebbi, on the same day they were collected. Samples awaiting processing were stored in a refrigerator at 4–8 °C. The socio-demographic and clinical status of the study patients whose samples were collected were recorded.

GeneXpert assay for detection of M. tuberculosis

Detection of M. tuberculosis from sputum specimens was determined using the GeneXpert assay machine (Cepheid, Sunnyvale, CA, USA). Briefly, an early morning sputum sample collected from patients was mixed with sample reagent in a ratio of 2:1 and allowed to settle at room temperature in the laboratory. Subsequently, 2 ml of the mixture was transferred into the GeneXpert cartridge and loaded into the GeneXpert machine for 2 h. The result was interpreted as “MTB detected” or “MTB not detected.”

Fungal culture, isolation, and identification

Potassium hydroxide (KOH) wet mounts

The potassium hydroxide (KOH) wet mounts were used to observe the presence or absence of fungal elements. Briefly, a drop of 10% KOH was placed on a clean glass slide using a Pasteur pipette. A small portion of sputum was mixed with a drop of KOH. The slide was covered with a coverslip and preserved in a moist chamber at room temperature for 30 min. The slide was viewed under the microscope using 10 and 40 objectives.

Gram staining for yeast cells

Briefly, a smear was made from the sputum samples on a clean glass slide. The cells and cell fragments are dried on a slide and stained with a standard Gram stain. The absence or presence of pseudohyphae in the sputum was recorded for gram-positive yeast-like cells. For differential staining, the slide was treated for 5 min with 1% phosphomolybdic acid, washed, and stained for 0.5 min with 1% aqueous methyl green. Whole or intact yeast cells appeared dark purple or black, while broken yeast cells with exposed cytoplasm were stained light purple.

Fungal culture

Sputum samples were streaked onto Sabouraud dextrose agar (SDA) to isolate pure colonies. The plates were inverted and incubated at 25–30 °C. The fungal growth on SDA plates was examined after seven days and held for four weeks before being reported as unfavorable. The morphology, texture, growth rate, colony surface, and pigmentation on the surface of SDA tubes were recorded. The fungal isolates on culture were identified using standard mycological procedures.

Lactophenol cotton blue staining

A drop of a small fragment of the fungal colony was placed on a grease-free glass slide containing lactophenol blue. The slide was covered with a coverslip, and the excess lactophenol blue stain was removed with blotting paper. The slide was viewed under the microscope using 10 and 40 objectives. The features and characteristics of fungal elements seen under the microscope were compared with established characteristic fungal features using mycology atlases.

Germ tube test

Candida albicans were identified by the germ tube tests. Yeast colonies were suspended in human serum in a test tube and incubated at 37 °C for 3 h. After observing a faintly turbid suspension, the suspension was examined under the microscope using 10 and 40 objectives to determine the presence or absence of germ tubes. The result is positive for C. albicans if germ tubes arose from the yeast cell and showed matching walls without any narrowing at their point of origin.

DNA extraction and amplification using PCR

Total DNA was extracted from 200 l of the suspension of the fungi isolate using a QIAamp Mini extraction kit according to the manufacturer’s protocol. The extracted DNA was stored at 200 ºC until used. The PCR was carried out using a Qiagen Top-Taq master mix kit. A 25-l reaction mix was prepared to contain 12.5 l of Qiagen Top Taq master mix and 1 l of 10 m-reach forward (ITS1-TCCGTAGGTGAACCTGCGG) and reverse (ITS4-TCCTCCGCTTATTGATATGC) primers [12]. These primers amplify approximately 600 base pairs of the ITS1-5.8S-ITS2 region of the ribosomal cistron: 1.5 l of coral load, 1 l of nuclease-free water, and 8 l of DNA template. The tubes were mixed and transferred into an Applied Biosystems 9700 computer programmed with the following cycling conditions: The first step was denaturation at 94° for 2 min, followed by 40 cycles at 94° for 30 s. The annealing was at 52° for 1 min, an extension at 72° for 1 min, and a final extension at 72° for 10 min. The amplicons were resolved in 1% agarose pre-stained with Safe Red. The gel image was viewed using a UV transilluminator (Analytik Jena US).

Statistical analysis

The data for each patient was entered and coded into Microsoft Excel 2013, version 1. The coded data were analyzed using Statistical Package for the Social Sciences (SPSS®, version 21; SPSS Inc., Chicago, IL, USA). Descriptive analysis was adopted to identify associations among variables. The associations between variables were presented as frequencies and percentages.

Results

Three hundred patients participated in the study. Of which 188 (63%) were males and 112 (37% were females). The patients’ ages ranged from 21 to 70 years old in 57 cases (19%), 31–40 years in 76 cases (25.3%), 41–50 years in 45 cases (15%), 51–60 years in 37 cases (12.3%), 61–70 years in 35 cases (11.7%), and more than 71 years in 7 cases (2.3%) (Table 1).

Table 1 Age and gender distribution within the confirmed cases of MTB patients in Kebbi State, Nigeria

In all the sputum samples analyzed, 50/300 (16.7%) patients had pulmonary tuberculosis, of which 8 (2.7%) were rifampicin-sensitive MTB and 2 (0.7%) were rifampicin-resistant MTB. Fungal pathogens were detected in 139/300 (47.3%) patients; 99/139 (71.2%) were primary infections, while 40/139 (29.4%) were secondary infections. Among the secondary infections, 33 (11%) were fungi coinfections with rifampicin-sensitive MTB coinfections, while 7 (2.3%) were fungi co-infected with rifampicin-resistant MTB coinfections (Table 2).

Table 2 Showing the occurrence and different types of infection within the confirmed cases of MTB patients in Kebbi State, Nigeria

Candida albican was the highest occurring fungal isolate with 44 (31.7%), followed by Blastomyces percursus with 43 (30.2%), and then Aspergillus fumigatus and Aspergillus niger with 32 (23%) and 14 (10.1%), respectively. The least common species were non-Candidal albicans, with 2 (1.4%) (Table 3). Of the 99 species responsible for primary infection, 33 (23.7%) were Blastomyces precursors, 30 (21.6%) were Candida species, and 21 (15.1%) were Aspergillus fumigatus (Table 4). The fungal pathogen with the highest frequency of secondary infection was Candida species 14 (10.1%), followed by Aspergillus fumigatus 11 (7.9%), then Blastomyces precursors 09 (6.5%) (Table 4).

Table 3 Frequency of fungus isolated by fungal culture from confirmed cases of MTB patients in Kebbi State, Nigeria (N = 139)
Table 4 Fungal causing primary and secondary pulmonary infection (N = 139)

The gel electrophoresis analysis of randomly selected species confirmed the presence of approximately 600 base pairs in the internal transcribed sequence region of the ribosomal cistron of the fungal species isolated from patients with confirmed cases of pulmonary tuberculosis and pulmonary mycosis, as shown in Fig. 1. From the figure, M denotes marker, 1 denotes Aspergillus species, 2 denotes Candida species, three denotes non-Candida species 1, 4 denotes non-Candida species 2, 5 denotes Blastomyces precursors, and NC denotes negative control accordingly.

Fig. 1
figure 1

Confirmed cases of pulmonary tuberculosis and pulmonary mycosis. M denotes marker, 1 denotes Aspergillus species, 2 denotes Candida species, three denotes non-Candida species 1, 4 denotes non-Candida species 2, 5 denotes Blastomyces precursors, and NC denotes negative control accordingly

Discussion

In Nigeria and many regions around the globe, there is a gradual increase in pulmonary fungal infections caused by opportunistic fungal pathogens, especially among patients with pulmonary tuberculosis. This study examined the level of pulmonary mycoses in patients with confirmed pulmonary tuberculosis in Kebbi State, Nigeria. The current study revealed a 16.7% prevalence of pulmonary tuberculosis. The prevalence of pulmonary tuberculosis is slightly lower than 19.7% in the study area [7, 8]. The decrease in the prevailing rate of pulmonary tuberculosis might be due to the rate of successful treatment outcomes recorded in the area [8].

The prevalence of pulmonary fungal pathogens was 71.2%, and a 29.4% prevalence of pulmonary mycoses was observed in patients with confirmed pulmonary tuberculosis. The study revealed a high prevalence rate of the fungal pathogen, similar to reports of 74% among presumptive tuberculosis cases in Nigeria [21]. The finding on the prevalence rate of pulmonary mycoses in patients with confirmed pulmonary tuberculosis in Gombe was 6% (Sani et al., 2020), compared to 29.4% in this study. Nevertheless, it is higher among HIV patients in Maiduguri, Nigeria (68%) [16]. Other prevalent rates were reported in Ghana among chronic pulmonary Aspergillosis patients coinfected with presumed tuberculosis (50%) [17], 68% in patients with lung cancer cases [15] a coinfection rate of (15.4%) in Africa and Asia among pulmonary tuberculosis patients [11, 14]. The difference in prevalence rate might be primarily due to the study area and population, study designs, sampling, and diagnostic methods. In HIV patients, the variation might be due to immune suppression by the virus, while in pulmonary tuberculosis, it could be due to the prolonged use of antibiotics, which upset patients’ normal flora by making the patient susceptible to mycoses [3, 10, 18].

Blastomyces precursor was the predominant species isolated (23.7%), of which 6.5% were coinfections with patients confirmed to have pulmonary tuberculosis. The finding is similar to studies reported in Zaria among pulmonary TB patients [1] and around the world among patients managed for pulmonary tuberculosis [9]. In Africa and Nigeria, pulmonary blastomycosis is a rare pathologic condition [6]. Thus, blastomycosis pathogens are misdiagnosed as bacterial pneumonia in their acute stage and treated as pulmonary tuberculosis when chronic in tuberculosis burden areas [11]. This was evident in reported clinical cases of a 37-year-old Nigerian diagnosed with pulmonary blastomycosis after receiving extended treatment for pulmonary tuberculosis [11, 18].

C. albicans was the second-most common fungal pathogen isolated in this study, accounting for 21.6%, and the most common fungal pathogen isolated in patients with pulmonary tuberculosis, accounting for 10.1%. C. albicans is an opportunistic fungal pathogen that affects individuals with a prior history of pathogenic infectious disease with prolonged treatment therapy [4, 13]. The combined prevalence of C. albicans was reported to be between 12.7 and 36 among tuberculosis patients [5, 10]. The high occurrence of this species among pulmonary patients indicates fungal colonization due to the extended use of antibiotics. C. albicans was previously reported and has remained the most frequently isolated Candida species in the clinical setting [20]. However, this study shows that the incidence rate of other candida and non-Candida infections is increasing in some countries, including sub-Saharan Africa.

Pulmonary aspergillosis is a rare pulmonary disease complicating other respiratory disorders such as tuberculosis. However, in this study, A. fumigatus was the second most prevalent secondary fungal pathogen, at 7.9%. This result is lower than the reported pooled prevalence of Aspergillus coinfection among patients with pulmonary tuberculosis in Asia (14.7%) and Africa (17.7%) [17]. The rate at which Aspergillus species cause pulmonary mycoses is attributed to their ability to survive different environmental conditions similar to the study area [19]. They also possess unique spore-producing structures that release spores or conidia into the atmosphere, easily penetrate deep into the branches of air tubes in the lungs, and survive [2, 10, 19].

Findings from this study showed that elderly pulmonary tuberculosis patients had higher cases of pulmonary fungal infection than younger ones. Most studies found that older age groups had higher rates of fungal infections and a link between age and mycoses and tuberculosis coinfection [2, 10, 18]. Undeniably, old age is a known risk factor for pulmonary fungal infection due to a weakening immune system, as one grows older. Pulmonary tuberculosis is prevalent among immunocompromised patients and the same with pulmonary mycoses because it is an opportunistic infection. However, it is common for pulmonary fungal pathogens to co-exist with other microbes in the same infection niche. Therefore, either of the two can manifest in immunocompromised patients. The suppressed immune system of an immunocompromised patient disrupts the fungal flora and worsens the underlying process of lung infection [10, 18]. Pulmonary fungal pathogens and infections are more prevalent in males than females recruited in this study. This corroborates previous studies that reported two-thirds of pathogenic mycoses were isolated in males compared with females [5, 10, 18]. The male might be exposed to much more airborne fungal spores and conidia because they stay outdoors due to their role in the community as breadwinners, compared to females, who are mostly indoors in the study area. This study did not report the comorbidities and radiology of the cases under investigation because the study was based on medical laboratory sciences of diagnosis of pulmonary tuberculosis infection and pulmonary fungal infection but not clinical case studies. However, all clinical and radiological findings showing the status of the patients recruited in the study were confirmed before they were included.

In conclusion, this study determined the prevalence rate of fungal pathogens among pulmonary tuberculosis patients. The most dominant species observed were Blastomyces, rarely reported in Africa and Nigeria. The two others were Aspergillus and Candida species. The study showed that many cases of this species, responsible for pulmonary mycosis, were misdiagnosed and treated as pulmonary tuberculosis. Thus, there is a need for improved surveillance and accurate diagnosis of pulmonary infections for proper treatment. In addition, due to the high prevalence of pulmonary fungal pathogens in this study, the radiology of the cases needs to be looked into in subsequent studies.